Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an update.
BioArctic AB reported a significant increase in royalties from Leqembi® and announced a new partnership with Novartis, which includes an upfront payment and potential future milestones. The company’s operations are bolstered by strong sales forecasts for Leqembi®, recent marketing authorizations, and promising study results, positioning them well in the neurodegenerative disease treatment market.
The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company specializing in the development of treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Their primary products include Leqembi® (lecanemab) for Alzheimer’s disease, and they focus on leveraging innovative technologies like their BrainTransporter™ platform to enhance drug delivery.
Average Trading Volume: 199,786
Technical Sentiment Signal: Buy
Current Market Cap: SEK23.64B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.